• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Lux Biosciences

edit

Lux Biosciences, Inc., a biotechnology company, develops medications to treat ophthalmic diseases. Its products include LX201, a silicone matrix ocular implant that enables the release of cyclosporine A to the eye for one year; Luveniq, an oral form of calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant that contains voclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. The company was founded in 2005 and is based in Jersey City, New Jersey.

Milestones

edit

• 
  Lux Biosciences added Eddy Anglade as Co-Founder and Chief Medical Officer .
  Posted 10/19/09 at 5:47pm
• 
  Lux Biosciences added Sidney L. Weiss as Co-Founder and Vice President of Program Management .
  Posted 10/19/09 at 5:47pm
• 
  Lux Biosciences added Ulrich Grau as Co-Founder.
  Posted 10/19/09 at 5:47pm
• 
  Lux Biosciences received $50M in Series B funding. (10/1/09)
  Posted 10/19/09 at 5:47pm via venturebeat.com

Videos

Screenshots

edit

Sources

1. Lux Biosciences scores $50M Series B for eye cure (venturebeat.com) [edit]